No Data
CStone Pharmaceuticals Showcases Breakthrough in Cancer Therapy
Founder Pharmaceuticals Group -B (02616.HK) announced the preclinical research data of CS2009 at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Gelonghui November 11th | Founder Pharmaceuticals-B (02616.HK) announced that the company released the pipeline 2.0 heavyweight product CS2009's preclinical data at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. Key highlights: • CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. • Preclinical data shows that CS2009 has significantly better anti-tumor activity than potential competitors. • CS2009 is expected to
Cornerstone Pharmaceuticals Group - B (02616) will announce the latest clinical data of CS5001 for lymphoma at the 66th American Society of Hematology (ASH) Annual Meeting.
Cornerstone Pharmaceuticals-B (02616) announced that the company will present at the 66th American Society of Hematology (ASH) Annual Meeting...
CStone Drug Gets UK Approval for First-Line Treatment of Non-Small Cell Lung Cancer
Cornerstone Pharmaceuticals-B (02616.HK) Regorafenib Monoclonal Antibody approved by the United Kingdom Medicines and Healthcare Products Regulatory Agency for first-line treatment of non-small cell lung cancer
October 31, Grong Hui丨Cornerstone Pharmaceuticals-B (02616.HK) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has approved the combination of Sogelid ankagen with platinum-based chemotherapy for first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) without sensitive EGFR mutations, or ALK, ROS1, RET gene tumor mutations. This is the second marketing authorization approval obtained by Sogelid ankagen in overseas markets following the approval of the European Commission. Key highlights• This is the second approval obtained by Sogelid ankagen outside of China following the approval of the European Commission.
Express News | UK's Mhra: Sugemalimab Approved to Treat Adult Patients With Non-Small Cell Lung Cancer
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
No Data
No Data
